ERBB2 and cancer: Among patients with aperformance status of 0–1 receiving HER2-negative cancer receiving first-lineCapOx/FOLFOX, median OS was 8.3, 8.8, and 8.6 months for EAC, GEJC, and GAC,respectively (p = 0.87; Supplemental Figure 5).